This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Cheung M , Testa JR
Diverse mechanisms of AKT pathway activation in human malignancy
Curr Cancer Drug Targets. 2013 Mar;13(3) :234-44
PMID: 23297823 PMCID: PMC3678724
AbstractAKT/PKB (Protein Kinase B) are central proteins mediating signals from receptor tyrosine kinases and phosphatidylinositol 3-kinase. AKT kinases are involved in a number of important cellular processes including cell proliferation and survival, cell size in response to nutrient availability, tumor invasion/metastasis, and angiogenesis.Various components of the AKT signaling pathway are encoded by tumor suppressor genes and oncogenes whose loss or activation, respectively, plays an important role in tumorigenesis. The growing body of evidence connecting deregulated AKT signaling with sporadic human cancers and inherited cancer predisposition syndromes is discussed. We also highlight new findings regarding the involvement of activating mutations of AKT1, AKT2, and AKT3 in somatic overgrowth disorders: Proteus syndrome, hypoglycemia with hypertrophy, and hemimegalencephaly, respectively. In addition, we review recent literature documenting the various ways the AKT signaling pathway is activated in human cancers and consequences for molecularly targeted therapies.
NotesCheung, Mitchell Testa, Joseph R CA06927/CA/NCI NIH HHS/United States CA77429/CA/NCI NIH HHS/United States P30 CA006927/CA/NCI NIH HHS/United States R01 CA077429/CA/NCI NIH HHS/United States Research Support, N.I.H., Extramural Review Netherlands Curr Cancer Drug Targets. 2013 Mar;13(3):234-44.